States, localities and tribes must ratify deal, which would settle suits alleging drugmaker promoted opioid painkillers without warning about addiction risks
Teva Pharmaceutical, which is based in Israel, said the proposed agreement will include no admission of wrongdoing. Photo: Kobi Wolf/Bloomberg News
Updated July 26, 2022 8:46 pm ET
Teva Pharmaceutical Industries Ltd. said it reached a national settlement agreement worth up to $4.25 billion to resolve thousands of lawsuits over its alleged role in the opioid crisis.
The proposed settlement is the latest move by a company seeking to resolve the costly litigation.
We are delighted that you’d like to resume your subscription.
You will be charged $ + tax (if applicable) for The Wall Street Journal. You may change your billing preferences at any time in the Customer Center or call Customer Service. You will be notified in advance of any changes in rate or terms. You may cancel your subscription at anytime by calling Customer Service.
Please click confirm to resume now.